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Objectives: Bipolar disorder imposes high economic burden, with direct costs 
estimated at $30.7 billion. Lurasidone is an atypical antipsychotic approved for the 
treatment of depressive episodes associated with bipolar I disorder. The objective of 
this study was to compare the cost-effectiveness of lurasidone and quetiapine XR in 
patients with bipolar depression. MethOds: A cost-effectiveness model was devel-
oped to compare lurasidone to quetiapine XR over a 3-month time horizon from a 
US payer perspective. Effectiveness inputs were based on indirect comparison of 
the proportion of patients achieving remission (MADRS total score ≤ 12 by week 6-8), 
obtained from lurasidone and quetiapine XR pivotal trials versus placebo. Resource 
utilization (emergency room visits, hospitalizations, and office visits) were obtained 
from an expert panel study. Drug costs were estimated using mean dose from clini-
cal trials and wholesale acquisition costs. Costs of resources were obtained from 
a retrospective database study of bipolar depression patients. Model results were 
tested using deterministic and probabilistic sensitivity analyses. Results: Over the 
3-month time horizon of the model, 52.0% of lurasidone patients achieved remission 
versus 43.2% of quetiapine XR patients. Mean emergency room visits, inpatient days, 
and office visits were lower for lurasidone patients (0.48, 2.1, 9.3) than quetiapine XR 
patients (0.50, 2.2, 9.6), respectively. Total costs were lower for lurasidone patients 
($4,447) than quetiapine XR patients ($4,546). Cost-effectiveness results showed 
that lurasidone was dominant over quetiapine XR. Model testing showed that the 
results were robust to changes in other parameters. One-way sensitivity analysis 
showed that the model may be sensitive to the drug cost/month, remission rate, or 
hospital cost/day. Probabilistic sensitivity analyses showed lurasidone has a 97.4% 
probability of being cost-effective compared to quetiapine XR at a willingness-to-pay 
threshold of $5,000 per remission. cOnclusiOns: Based on this model, lurasidone 
is cost-effective compared to quetiapine XR in patients with bipolar depression.
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Objectives: Generalized Anxiety Disorder (GAD) affects around 6.8 million U.S. 
adults. It places a considerable economic burden upon patients and payers alike. 
Selective serotonin reuptake inhibitors (SSRIs) are among the first-line therapy for 
treating GAD. Currently, Escitalopram and Paroxetine are the only SSRIs approved 
by U.S. FDA for treating GAD. To assess, from a third party payer’s perspective, the 
cost-effectiveness of Escitalopram and Paroxetine in the treatment of GAD in the 
U.S. MethOds: A decision analytic model with a 12 month time horizon, adapted 
to the U.S. setting was constructed. Outcome measured as a reduction in Hamilton 
Anxiety Scale (HAMA) scores, and adverse event probabilities were obtained from a 
head-to-head randomized trial. Resource utilization and associated costs were esti-
mated from standard national sources. Analyses from a third party payer’s perspec-
tive focused on the direct medical cost of treatment e.g. drugs, physician visits and 
dispensing cost. Annual cost per person for the treatment was calculated and the cost-
effectiveness of the treatment options was measured. All costs were reported in 2013 
US Dollars. Cost-effectiveness was expressed as the incremental cost-effectiveness 
ratio (ICER). Sensitivity analysis on key input parameters and Monte Carlo simula-
tion was performed to measure the robustness of the model. Results: Escitalopram 
dominated Paroxetine by having both, lower total annual cost ($4587 vs. $5243, respec-
tively) and better outcomes (14 HAMA vs. 13 HAMA point reduction, respectively).The 
ICER was found to be -$656/HAMA point which indicates improved effectiveness along 
with reduction in costs by adopting Escitalopram over Paroxetine. Sensitivity analysis 
demonstrated the robustness of the model. cOnclusiOns: Escitalopram appears 
to be cost-effective compared with Paroxetine in treatment of GAD in the U.S. from 
a third party payer’s perspective.
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Objectives: The objectives of this study are: (1) to estimate the expected health 
outcomes of atypical antipsychotics (AAPs) and other non-stimulant attention-def-
icit/hyperactivity disorder (ADHD) medications based on trade-offs between clinical 
effectiveness and adverse effects and (2) to evaluate the cost-effectiveness of AAPs 
compared to other non-stimulant ADHD medications. Both aims target children 
and adolescents with ADHD who have failed prior stimulant therapy. MethOds: 
We used decision analysis to compare three alternatives for treating children and 
adolescents with ADHD who failed initial stimulant treatment: (1) AAPs (2) a selec-
tive norepinephrine reuptake inhibitor (atomoxetine), and (3) selective a2-adrenergic 
agonists (clonidine and guanfacine). Probability estimates and quality adjusted life 
year (QALY) weights were derived from a literature review. One-way deterministic 
sensitivity analyses were performed to evaluate the robustness of the results. Cost-
effectiveness was estimated using the expected health outcomes derived from the 
decision analysis and expected costs from the literature. A Monte Carlo simulation 
was performed as a probabilistic sensitivity analysis. Results: After one year of 
ADHD pharmacotherapy, clonidine/guanfacine provided the highest expected QALY 
(0.95) followed by atomoxetine (expected QALY 0.94). Atypical antipsychotics yielded 
the lowest health outcome with an expected QALY of 0.84. In the cost-effectiveness 
analysis, the AAP strategy was dominated as it was less effective and more costly 
ance claims database (TruvenHealth MarketScan® Medicaid) from January 2007 
to June 2012. Patients with at least two treatment episodes in the first year after 
the initial filled prescription were identified. The end of a treatment episode was 
defined as a period of 60 days with no filled BUP/NAL prescriptions following 
the theoretical end of the last filled prescription. An ordered logistic regression 
model was used to analyze the impact of initial treatment episode duration on the 
number of new episodes in the year following the end of the first episode. Health 
care resource utilization and related costs during the first year after initiation 
were compared between the two groups. Results: 2,223 patients were included 
in the analysis. During the first year, 86% of patients had only one treatment 
episode, 13% had two and 1% had three. Compared to patients treated continu-
ously over 12 months, the multiple treatment episode groups had lower medica-
tion costs (-$2,877) but higher psychiatric inpatient costs (+$720), non-psychiatric 
inpatient costs (+$2001) and emergency room costs over 12 months. Total health 
care costs over 12 months were higher among multiple treatment episode patients 
($16,583 vs. $15.123, p= 0.0004). cOnclusiOns: Despite lower medication costs, 
total health care costs over 12 months were higher among patients with multiple 
treatment episodes compared to patients treated continuously.
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Objectives: Preliminary data from a multicenter, open-label mirror study of 
patients with schizophrenia aged 18–65 years (Kane et al. J Med Econ. 2013;16:917) 
demonstrated that switching from oral standard of care (SOC) antipsychotics 
to aripiprazole once-monthly (AOM) reduced total psychiatric hospitalization 
rates from 41.5% in the SOC 6-month retrospective period to 14.2% in the AOM 
6-month prospective period (p< 0.0001). A subgroup of patients with at least 1 
psychiatric hospitalization while receiving oral SOC in the retrospective period 
was analyzed to estimate health care cost savings associated with AOM treatment 
initiation. MethOds: An economic model was developed to examine the impact 
on costs and outcomes of switching to AOM. Cost for hospitalizations, hospi-
tal length of stay, and cost of drug therapy were estimated for a subgroup of 76 
patients with schizophrenia who entered the ongoing mirror study (NCT01432444) 
and had at least 1 psychiatric hospitalization during the retrospective period. 
Cost estimates were obtained from HealthCare Costs and Utilization Project, pub-
lished literature, and US Bureau of Labor Statistics. Adjustments were made to 
estimate additional resource use for patients who discontinued the study (lost to 
follow-up, adverse events, met protocol/investigator withdrawal criteria, protocol 
deviation, lack of efficacy) and thus did not have complete data on resource use 
from the trial. Results: Among the 76 patients with hospitalizations during the 
retrospective period, hospitalizations were reduced to 22.4% (17/76, p< 0.0001) in 
the prospective AOM period. Total cost during the prospective period ($23,313) 
after switching to AOM was lower than that in the retrospective period ($36,415) 
by $13,102 per patient. Hospitalizations per patient were reduced from 1.16 to 
0.53. Increased cost due to AOM initiation ($6,010) was offset by reduced cost 
for hospitalizations (–$19,112). cOnclusiOns: Among patients with previous 
psychiatric hospitalizations, treatment with AOM may reduce total cost of care 
for health plans.
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Objectives: Management of patients with chronic relapsing schizophrenia is dif-
ficult and costly. We assessed the cost-effectiveness of paliperidone palmitate long-
acting injectable (PP-LAI) versus risperidone depot (RIS-LAI), olanzapine pamoate 
(OLZ-LAI), oral olanzapine (oral-OLZ) and oral clozapine (CLOZ) from the viewpoint 
of the Finnish National Health Service. MethOds: We expanded and adapted a 
1-year decision tree model that had been previously validated for Finland, with 
assistance from an expert panel. Patients started in a stable state and were treated 
as per standard procedures in Finland. Drug doses, success and relapse rates were 
determined from published clinical studies. Patient management was guided by 
expert opinion. Health state utilities were derived from the literature. Only direct 
costs were considered, including hospitalization and other institutional care, medi-
cal and nursing care, and drugs. Prices were obtained from standard lists. Outcomes 
included quality-adjusted life-years (QALYs), rates of rehospitalization and days 
with stable disease. The primary economic outcome was the incremental cost/QALY. 
One-way sensitivity analyses were performed on all pertinent costs and clinical 
inputs. Results between drugs were tested in a pairwise fashion with 10,000 Monte 
Carlo simulations each, using standard distributions for all variables. Results: 
Expected costs were € 10,691 for PP-LAI, € 12,462 for RIS-LAI, € 12,496 for OLZ-LAI, 
€ 27,270 for oral-OLZ and € 23,258 for CLOZ. QALYs were 0.829, 0.813, 0.821, 0.739 
and 0.523, respectively. Rehospitalizations were 0.25, 0.30, 0.29, 0.61, and 1.88, 
respectively and days with stable disease were 329.3, 326.2, 325.1, 283.9 and 215.6, 
respectively. In the base-case, PP-LAI dominated all other drug choices. One-way 
sensitivity analyses indicated that results were insensitive to drug costs but sensi-
tive to plausible changes in rates of adherence or hospitalization. In probability 
sensitivity analyses, results were robust overall with ICERs significantly favouring 
PP-LAI (P< 0.001). cOnclusiOns: PP-LAI was cost-effective in Finland for chronic 
relapsing schizophrenia.
